Display options
Cite
Ciesielski J, Su TP, Tsai SY. Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration. Receptors Clin Investig. 2016;3(1)doi: 10.14800/rci.1114.
Ciesielski, J., Su, T. P., & Tsai, S. Y. (2016). Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration. Receptors & clinical investigation, 3(1), . https://doi.org/10.14800/rci.1114
Ciesielski, Jenna, et al. "Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration." Receptors & clinical investigation vol. 3,1 (2016). doi: https://doi.org/10.14800/rci.1114
Ciesielski J, Su TP, Tsai SY. Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration. Receptors Clin Investig. 2016;3(1). doi: 10.14800/rci.1114. PMID: 27077074; PMCID: PMC4827442.
Copy Download .nbib Format: NLM
Share it on

Receptors Clin Investig. 2016;3(1). doi: 10.14800/rci.1114.

Myristic acid hitchhiking on sigma-1 receptor to fend off neurodegeneration.

Receptors & clinical investigation

Jenna Ciesielski, Tsung-Ping Su, Shang-Yi Tsai

Affiliations

  1. Cellular Pathobiology Section, Integrative Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, Maryland 21224, USA.

PMID: 27077074 PMCID: PMC4827442 DOI: 10.14800/rci.1114

Abstract

Neurodegenerative diseases are linked to tauopathy as a result of cyclin dependent kinase 5 (cdk5) binding to its p25 activator instead of its p35 activator and becoming over-activated. The overactive complex stimulates the hyperphosphorylation of tau proteins, leading to neurofibrillary tangles (NFTs) and stunting axon growth and development. It is known that the sigma-1 receptor (Sig-1R), an endoplasmic reticulum chaperone, can be involved in axon growth by promoting neurite sprouting through nerve growth factor (NGF) and tropomyosin receptor kinase B (TrkB)

References

  1. Biochemistry. 2010 Jul 6;49(26):5482-93 - PubMed
  2. Trends Mol Med. 2009 Mar;15(3):112-9 - PubMed
  3. Acta Neuropathol. 1994;88(1):1-6 - PubMed
  4. Ann Nucl Med. 2008 Apr;22(3):151-6 - PubMed
  5. J Neurochem. 2005 Sep;94(6):1535-45 - PubMed
  6. Ther Clin Risk Manag. 2008 Jun;4(3):605-15 - PubMed
  7. Biochem Biophys Res Commun. 2000 Jul 21;274(1):16-21 - PubMed
  8. Annu Rev Cell Dev Biol. 2011;27:465-91 - PubMed
  9. Nature. 1999 Dec 9;402(6762):615-22 - PubMed
  10. Biochem Soc Symp. 2001;(67):81-8 - PubMed
  11. Biochem Soc Trans. 2015 Apr;43(2):229-34 - PubMed
  12. J Pharmacol Exp Ther. 2002 Dec;303(3):1227-37 - PubMed
  13. CNS Neurosci Ther. 2013 Sep;19(9):705-13 - PubMed
  14. J Biol Chem. 2012 Dec 14;287(51):43156-69 - PubMed
  15. J Pharmacol Exp Ther. 2003 Aug;306(2):718-25 - PubMed
  16. Neurosci Res. 2009 Sep;65(1):88-97 - PubMed
  17. Nature. 2000 May 18;405(6784):360-4 - PubMed
  18. J Neurochem. 2008 Aug;106(3):1325-36 - PubMed
  19. Brain Res Brain Res Rev. 2000 Aug;33(1):95-130 - PubMed
  20. J Cell Sci. 2000 Mar;113 ( Pt 6):975-83 - PubMed
  21. Mol Pharmacol. 2010 Apr;77(4):517-28 - PubMed
  22. J Biol Chem. 2000 Jun 2;275(22):17166-72 - PubMed
  23. Neurosignals. 2003 Sep-Oct;12 (4-5):221-9 - PubMed
  24. Cell Mol Life Sci. 2002 Oct;59(10):1668-80 - PubMed
  25. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5562-6 - PubMed
  26. Proc Natl Acad Sci U S A. 2015 May 26;112(21):6742-7 - PubMed
  27. Trends Neurosci. 2009 Mar;32(3):142-9 - PubMed
  28. J Biol Chem. 1998 Sep 11;273(37):24057-64 - PubMed
  29. PLoS One. 2013 Oct 08;8(10):e75760 - PubMed
  30. PLoS Genet. 2007 Jun;3(6):e98 - PubMed
  31. J Comp Neurol. 2002 May 6;446(3):257-66 - PubMed
  32. FEBS Lett. 2006 May 22;580(12):2922-7 - PubMed
  33. Biochim Biophys Acta. 2005 Jan 3;1739(2-3):280-97 - PubMed
  34. Mol Biol Cell. 2004 Jan;15(1):111-20 - PubMed
  35. J Biol Chem. 1995 May 5;270(18):10990-8 - PubMed
  36. Cancer Res. 2007 Dec 1;67(23):11166-75 - PubMed

Publication Types

Grant support